PL2968146T3 - Kompozycja liposomalna z kontrolowanym uwalnianiem leku - Google Patents

Kompozycja liposomalna z kontrolowanym uwalnianiem leku

Info

Publication number
PL2968146T3
PL2968146T3 PL14764361T PL14764361T PL2968146T3 PL 2968146 T3 PL2968146 T3 PL 2968146T3 PL 14764361 T PL14764361 T PL 14764361T PL 14764361 T PL14764361 T PL 14764361T PL 2968146 T3 PL2968146 T3 PL 2968146T3
Authority
PL
Poland
Prior art keywords
drug release
controlled drug
liposome composition
release liposome
composition
Prior art date
Application number
PL14764361T
Other languages
English (en)
Inventor
Pei Kan
Yun-Long Tseng
Han Chun Ou
Original Assignee
Taiwan Liposome Company, Ltd.
Tlc Biopharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiwan Liposome Company, Ltd., Tlc Biopharmaceuticals, Inc. filed Critical Taiwan Liposome Company, Ltd.
Publication of PL2968146T3 publication Critical patent/PL2968146T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL14764361T 2013-03-15 2014-03-15 Kompozycja liposomalna z kontrolowanym uwalnianiem leku PL2968146T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361792850P 2013-03-15 2013-03-15
PCT/US2014/029907 WO2014145187A1 (en) 2013-03-15 2014-03-15 Controlled drug release liposome composition
EP14764361.3A EP2968146B1 (en) 2013-03-15 2014-03-15 Controlled drug release liposome composition

Publications (1)

Publication Number Publication Date
PL2968146T3 true PL2968146T3 (pl) 2020-06-29

Family

ID=51537897

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14764361T PL2968146T3 (pl) 2013-03-15 2014-03-15 Kompozycja liposomalna z kontrolowanym uwalnianiem leku

Country Status (18)

Country Link
US (1) US9700511B2 (pl)
EP (1) EP2968146B1 (pl)
JP (2) JP6449848B2 (pl)
KR (1) KR101925507B1 (pl)
CN (2) CN105392474B (pl)
AU (1) AU2014233308B2 (pl)
BR (1) BR112015023481B1 (pl)
CA (1) CA2906149C (pl)
DK (1) DK2968146T3 (pl)
ES (1) ES2777223T3 (pl)
HK (1) HK1216010A1 (pl)
NZ (1) NZ711500A (pl)
PL (1) PL2968146T3 (pl)
RU (1) RU2712157C2 (pl)
SG (2) SG10201707474XA (pl)
TW (2) TWI592168B (pl)
WO (1) WO2014145187A1 (pl)
ZA (1) ZA201506214B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10220095B2 (en) * 2013-03-15 2019-03-05 Taiwan Liposome Company, Ltd Controlled drug release liposome compositions and methods thereof
AU2015301234A1 (en) * 2014-08-04 2017-06-15 Zoneone Pharma, Inc. Remote loading of sparingly water-soluble drugs into lipid vesicles
CN110381922A (zh) * 2017-01-18 2019-10-25 淡马锡生命科学研究院有限公司 超稳定脂质体增加对有丝分裂细胞的靶向作用
WO2020055713A1 (en) * 2018-09-10 2020-03-19 Taiwan Liposome Co., Ltd. Sustained-release ophthalmic pharmaceutical compositions and uses thereof
JP7482487B2 (ja) * 2018-09-13 2024-05-14 タイワン リポソーム カンパニー リミテッド 鎮静薬を含む徐放性医薬組成物およびその使用
TWI767149B (zh) * 2018-10-17 2022-06-11 台灣微脂體股份有限公司 含有免疫調節劑的緩釋藥物組合物及其用途
CN109260155B (zh) * 2018-11-05 2021-04-06 杭州高田生物医药有限公司 伊立替康脂质体制剂及其制备与应用
TW202317070A (zh) * 2021-09-30 2023-05-01 大陸商上海濟煜醫藥科技有限公司 酒石酸長春瑞濱脂質體及其原料組合物、製備方法和應用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010051183A1 (en) * 1989-10-20 2001-12-13 Alza Corporation Liposomes with enhanced circulation time and method of treatment
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
WO2003018018A2 (en) 2001-08-24 2003-03-06 Neopharm, Inc. Vinorelbine compositions and methods of use
GB0312309D0 (en) 2003-05-29 2003-07-02 Gaslini Children S Hospital G Targeted liposome
EP1557429A1 (en) * 2004-01-23 2005-07-27 Vectron Therapeutics AG Site-directed coupling of proteins
EP1746976B1 (en) * 2004-05-03 2017-01-11 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery
EP1817004A2 (en) * 2004-11-15 2007-08-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combination therapy associating preferably a ceramide with a cytotoxic drug
AU2006307460A1 (en) 2005-10-26 2007-05-03 New York University A method for preparing liposomes and uses thereof
CN100375621C (zh) 2005-11-04 2008-03-19 唐星 长春瑞滨脂质微球注射液及其制备方法
CN100438855C (zh) 2006-01-19 2008-12-03 浙江大学 重酒石酸长春瑞滨脂质体及其冻干粉针与制备方法
CN100998562A (zh) 2006-12-31 2007-07-18 西安力邦医药科技有限责任公司 注射用长春瑞滨脂质体的制备方法
CN101129375B (zh) 2007-07-06 2010-12-22 浙江大学 长春瑞滨固体脂质纳米粒与其冻干制剂及制备方法
TW200922630A (en) * 2007-09-26 2009-06-01 Nat Health Research Institutes Liposome compositions useful for tumor imaging and treatment
CN101933904B (zh) 2009-07-01 2011-11-16 齐鲁制药有限公司 一种长春瑞滨长循环脂质体制剂及其制备方法
EP2531175A2 (en) * 2010-02-01 2012-12-12 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Liposomes comprising amphipathic drugs and method for their preparation
CN101849915A (zh) 2010-05-26 2010-10-06 辽宁中医药大学 异长春花碱隐形脂质体冻干粉针剂及其制备方法
CN101843584B (zh) 2010-06-02 2012-05-30 北京大学 一种全反式维甲酸与脂质体的复合物及其应用

Also Published As

Publication number Publication date
EP2968146A1 (en) 2016-01-20
TWI592168B (zh) 2017-07-21
SG11201507110WA (en) 2015-10-29
AU2014233308B2 (en) 2018-10-25
US20160030340A1 (en) 2016-02-04
EP2968146A4 (en) 2016-11-02
BR112015023481A2 (pt) 2017-07-18
EP2968146B1 (en) 2020-02-19
JP6752868B2 (ja) 2020-09-09
CN109350600B (zh) 2021-10-29
WO2014145187A1 (en) 2014-09-18
RU2015135629A3 (pl) 2018-03-06
TW201534353A (zh) 2015-09-16
US9700511B2 (en) 2017-07-11
CA2906149C (en) 2020-09-15
SG10201707474XA (en) 2017-10-30
RU2015135629A (ru) 2017-03-10
JP2016518340A (ja) 2016-06-23
NZ711500A (en) 2020-05-29
BR112015023481B1 (pt) 2022-12-20
AU2014233308A1 (en) 2015-09-17
CN105392474B (zh) 2019-01-08
JP6449848B2 (ja) 2019-01-09
JP2019055985A (ja) 2019-04-11
ES2777223T3 (es) 2020-08-04
RU2712157C2 (ru) 2020-01-24
HK1216010A1 (zh) 2016-10-07
ZA201506214B (en) 2022-03-30
CA2906149A1 (en) 2014-09-18
KR101925507B1 (ko) 2018-12-05
KR20150129727A (ko) 2015-11-20
CN105392474A (zh) 2016-03-09
TW201500061A (zh) 2015-01-01
BR112015023481A8 (pt) 2019-12-03
TWI660749B (zh) 2019-06-01
CN109350600A (zh) 2019-02-19
DK2968146T3 (da) 2020-03-16

Similar Documents

Publication Publication Date Title
ZA201905426B (en) Drug combinations
HRP20180684T1 (hr) Kombinacija lijekova
RS59756B1 (sr) Kombinovana farmaceutska kompozicija
EP2991639A4 (en) PHARMACEUTICAL FORMULATIONS WITH CONTROLLED RELEASE
HK1216010A1 (zh) 控制藥物釋放的脂質體組合物
HK1216839A1 (zh) 調整釋放製劑
SG11201601477VA (en) Pharmaceutical composition
GB2502402B (en) Controlled drug release
IL242704B (en) Pharmacy preparation
HK1220143A1 (zh) 藥物組合物
GB2510754B (en) Controlled drug release
HK1195491A1 (zh) 受控藥物釋放
GB201314372D0 (en) Controlled drug release
GB201304625D0 (en) New pharmaceutical composition